Company intelligence / Profile preview

DiaMo Narcotics

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

DiaMo Narcotics is a South Korean biotechnology company focused on developing next-generation analgesics and treatments for opioid-related disorders. The company specializes in the design of bifunctional opioid agonists that target both mu and delta opioid receptors to provide potent pain relief with a significantly reduced risk of addiction and respiratory depression compared to traditional opioids. Their lead research efforts are centered on creating safer alternatives for managing chronic and cancer-related pain while addressing the global opioid crisis through innovative medicinal chemistry.

Therapeutic areas: OncologyNeurologyPsychiatry
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on DiaMo Narcotics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DiaMo Narcotics.

Explore the full profile